Adasuve (loxapine) is a small molecule pharmaceutical. Loxapine was first approved as Adasuve on 2012-12-21. It is used to treat psychotic disorders and schizophrenia in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(4) dopamine receptor, 5-hydroxytryptamine receptor 2C, D(3) dopamine receptor, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 6, histamine H1 receptor, potassium channel subfamily T member 1, and 5-hydroxytryptamine receptor 7. Loxapine's patents are valid until 2026-10-23 (FDA).
|Indication||bipolar disorder, psychotic disorders, schizophrenia|
|Drug Class||Tricyclic compounds|